This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kwok, C. S. Articles by Liao, S.-K. Search for Related Content PubMed PubMed Citation Articles by Kwok, C. S. Articles by Liao, S.-K.

Uptake Kinetics of Monoclonal Antibodies by Human Malignant Melanoma Multicell Spheroids¹

Hamilton Regional Cancer Centre, Ontario Cancer Foundation [C. S. K., S. E. C.], and Departments of Radiology [C. S. K., S. E. C.] and Pathology [S-K. L.], McMaster University, Hamilton, Ontario, Canada, L8V 1C3

Detailed uptake kinetics by multicell spheroids of three tumor associated monoclonal antibodies was investigated. The spheroids were established from a human melanoma cell line and the human colon adenocarcinoma cell line HT29 as in vitro models of poorly vascularized micrometastases in vivo. The selected antibodies 96.5, 140.240, and OST15 showed a wide range of reactivity against the melanoma cell but they all had negligible binding with the colon cancer cell. Uptake of the antibodies by small spheroids (about 300 µm diameter) was generally sigmoidal in shape with respect to incubation time, and amount of uptake followed the same trend of immunoreactivity of the antibodies with single cells. The correlation was weaker for spheroids with diameter greater than 500 µm presumably due to the increasing size of the necrotic core. By varying the concentration of the antibodies in the incubation medium from tracer dose (0.2 µg/ml) to a higher dose (3 µg/ml), negligible changes in the amount of antibodies bound with their target spheroids were observed. Nonspecific binding between antibodies and spheroids, however, resulted in proportional increase in uptake.

¹ Research supported by the National Cancer Institute of Canada.

² To whom requests for reprints should be addressed.

³ Present address: Biotherapeutic, Franklin, TN 37064.

Received 7/27/87. Revised 12/ 8/87. Accepted 1/11/88.

This article has been cited by other articles:

				C. P. Graff and K. D. Wittrup Theoretical Analysis of Antibody Targeting of Tumor Spheroids: Importance of Dosage for Penetration, and Affinity for Retention Cancer Res., March 15, 2003; 63(6): 1288 - 1296. [Abstract] [Full Text] [PDF]

				J. Chen, Z. Cheng, T. J. Hoffman, S. S. Jurisson, and T. P. Quinn Melanoma-targeting Properties of 99mTechnetium-labeled Cyclic {{alpha}}-Melanocyte-stimulating Hormone Peptide Analogues Cancer Res., October 1, 2000; 60(20): 5649 - 5658. [Abstract] [Full Text]

				J. Hakulinen and S. Meri Complement-Mediated Killing of Microtumors in Vitro Am. J. Pathol., September 1, 1998; 153(3): 845 - 855. [Abstract] [Full Text] [PDF]